Reports Q4 revenue $184.0M, consensus $182.8M. “Our innovation engine has consistently delivered transformational technologies that have enabled our customers to expand the frontiers of science,” said Serge Saxonov, Co-founder and CEO. “We’re building on last year’s extraordinary launch of Xenium with new, franchise-defining products in each of our three platforms that will take our portfolio to the next level. Our priority is to ensure our customers’ success with these new products as we work together to deliver on the full promise and potential of single cell and spatial biology to advance human health.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TXG:
- 10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024
- Canaccord still bullish on 10x Genomics, PacBio despite reducing 2024 estimates
- 10x Genomics price target lowered to $60 from $65 at Deutsche Bank
- 10x Genomics price target raised to $55 from $45 at Barclays
- 10x Genomics’s preliminary Q4 results ahead of Street estimates, says Canaccord
